Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent
1982-07-15
1984-08-28
Phillips, Delbert R.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reduced antigenicity, reduced ability to bind complement, or...
2601125R, A61K 3700, C07C10352
Patent
active
044683820
ABSTRACT:
A hybrid protein toxic to cells having linear neuropeptide receptors such as TRH receptors comprising a linear neuropeptide such as TRH covalently bonded to CRM 45 is useful for treatment of tumors.
REFERENCES:
patent: 4340535 (1982-07-01), Voisin et al.
Miskimins et al., Biochem. Biophys. Res. Commun., vol. 91, pp. 143-151, (1979).
Cawley et al., Cell, vol. 22, pp. 563-570, (1980).
Miskimins et al., PNAS (USA), vol. 78, pp. 445-449, (1981).
Uchida et al., Nature, (New Biology), vol. 233, pp. 8-11, (1971).
Chang et al., J. Biol. Chem., vol. 252, pp. 1515-1522, (1977).
Oeltmann et al., J. Biol Chem., vol. 254, pp. 1028-1032, (1979).
Bacha Patricia
Murphy John R.
Reichlin Seymour
New England Medical Center, Inc.
Phillips Delbert R.
LandOfFree
Polypeptide-toxin hybrid protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptide-toxin hybrid protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptide-toxin hybrid protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-877039